Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: danoprevir Clear all
Completed Phase 2 Interventional

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

NCT01483742
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

NCT01588002
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, efavirenz, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

NCT01392755
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, omeprazole, ranitidine, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

NCT00963885
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

NCT01592305
View directory record Official record
Conditions
Healthy Volunteer
Interventions
atazanavir, danoprevir, ritonavir, tenofovir disoproxil fumarate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

NCT01185873
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

NCT01331850
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

NCT01164488
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, ketoconazole, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

NCT01531647
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, raltegravir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

NCT01418274
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, escitalopram, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

NCT01220947
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Danoprevir, Pegasys, Ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on the Interaction Between Danoprevir/Ritonavir and Methadone

NCT01389544
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, methadone, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Anaheim, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

NCT01514968
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cyclosporine, danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

NCT01519336
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, darunavir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:50 AM EDT